Latest news with #Euronext
Business Wire
9 hours ago
- Business
- Business Wire
Poxel Announces the Opening of Reorganization Proceedings
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces today the opening of reorganization proceedings. Opening of judicial reorganization proceedings On July 29, 2025, POXEL announced in a press release that it had filed for insolvency with the Lyon Court of Economic Activities (the " Court") and requested the opening of reorganization proceedings. Following a hearing held on August 5, 2025, the Court decided to initiate reorganization proceedings. The Company will continue to operate during the six-month observation period, in accordance with legal provisions. During this period, POXEL will examine all options available to it to continue its activities, including a continuation plan. The Company will keep all stakeholders informed as necessary of developments in its situation and the progress of the proceedings. Resumption of trading in POXEL shares (Euronext: POXEL - FR0012432516) The Company has asked Euronext to resume trading of POXEL shares as of August 11, 2025, at market opening. About Poxel Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is otherwise not responsible for the content of external hyperlinks referred to in this press release.
Business Wire
a day ago
- Business
- Business Wire
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (the 'Company' or 'Celyad Oncology'), today announces the below information following the issuance, on August 5, 2025, of 3,333,333 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company's share capital has been increased to 9,216,154.53 EUR and is represented by 44,761,905 shares. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions. Figures – Modified on August 5, 2025, following the capital increase: Contact person for regulated information (financial, transparency) By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@ Further questions about the content of this release can be sent to investors@ About Celyad Oncology Celyad Oncology is a cutting-edge biotechnology company focused primarily on unlocking the potential of its proprietary CAR-T technology platforms and intellectual property. The Company is headquartered in Mont-Saint-Guibert, Belgium. For more information, visit Celyad Oncology Forward-Looking Statement This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company's updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company's IP, statements regarding the Company's financial statements and cash runway, statements regarding the Company's future fundraising plans, statements regarding the Company's hiring plans, and statements regarding the continuation of the Company's existence. The words 'will,' 'potential,' 'continue,' 'target,' 'project,' 'should' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management's current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company's ability to continue as a going concern; the Company's ability to realize the expected benefits of its updated strategic business model; the Company's ability to develop its IP assets and enter into partnerships with outside parties; the Company's ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company's ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report of Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology's actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Business Wire
a day ago
- Business
- Business Wire
Groupe SEB: Monthly Disclosure of the Total Number of Shares and Voting Rights – 31.07.2025
ECULLY, France--(BUSINESS WIRE)--Regulatory News: Issuer Numbers of shares and voting rights : 30 June 2025 31 July 2025 Shares in Euronext (1) 55 337 770 55 337 770 Theoretical voting rights (2) 80 480 863 80 331 657 Effective voting rights 79 926 909 79 774 703 Expand (1) Shares with a par value of 1€ (2) Including voting rights attached to shares for which the right is revoked (own controlled shares) A statutory clause imposes an obligation to declare any crossing thresholds in addition to those provided by law, to any person who comes to hold, directly or indirectly, as defined by Articles L. 233-7 and L. 233-9 of the French Commercial Code, 0.5% of the share capital or voting rights, or any multiple of that percentage. Find us on World reference in small domestic equipment and professional coffee machines, Groupe SEB operates with a unique portfolio of 40 top brands (including Tefal, Seb, Rowenta, Moulinex, Krups, Lagostina, All-Clad, WMF, Emsa, Supor), marketed through multi-format retailing. Selling more than 400 million products a year, it deploys a long-term strategy focused on innovation, international development, competitiveness, and client service. Present in over 150 countries, Groupe SEB generated sales €8 billion in 2023 and has more than 31,000 employees worldwide.
Finextra
2 days ago
- Business
- Finextra
Bluefin partners Raiffeisen on payment security in South Tyrol
Bluefin, the global leader in payment and data security, today announced a strategic partnership with Cassa Centrale Raiffeisen, a leading banking institution, ICIT, an innovative Independent Software Vendor (ISV), and Worldline, [Euronext: WLN], a global leader in payment services. 0 This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. This collaboration brings a new level of payment and data security to All-In-One (AIO) payment devices across Italy's South Tyrol region. South Tyrol is known for its booming economy and status as a premier tourist destination. The thriving tourism, hospitality, and retail sectors make it an ideal environment for advanced and innovative payment technology. The partnership not only facilitates the immediate rollout of AIO devices but also sets the stage for future expansions into unattended and e-commerce payment solutions. By leveraging the expertise of Bluefin, businesses in the region will benefit from robust security and efficient payment processing. 'At Bluefin, we are excited to collaborate with leading players and ISVs to deliver validated P2PE solutions across Europe and all global regions,' said Cheng Chieh Chen, Bluefin's Senior Vice President, Europe. 'Together with Cassa Centrale Raiffeisen, ICIT and Worldline, we are committed to transforming the payment landscape in South Tyrol by delivering payment innovation, security, and enhanced customer experiences to this vibrant market.' 'As the main provider of banking services for Raiffeisen Banks in South Tyrol and as corporate banking experts, we are constantly trying to find new products and solutions to better meet the needs and requirements of our corporate clients and to optimize their work processes. Thanks to our partnership with Bluefin, ICIT and Worldline, we provide innovative and state-of-the-art payment systems to gastronomic businesses in South Tyrol. Thus, we contribute to the economic development of our province,' explained Simon Ladurner, General Director of Cassa Centrale Raiffeisen. 'This ISV partnership, in which Worldline is providing secure and robust payment processing services, will enhance the delivery of an expanded, competitive, and innovative payment offering tailored to the Italian market. Thanks to the partner's combined international experience and local Italian expertise, merchants are assured to receive payment solutions that effectively meet their needs," declared Julia Rachor, Head of SMB Central Sales Management at Worldline.
Business Wire
3 days ago
- Business
- Business Wire
Bluefin Announces Strategic Partnership with Cassa Centrale Raiffeisen in South Tyrol, ICIT and Worldline to Deliver All-In-One Payment Security
ATLANTA--(BUSINESS WIRE)--Bluefin, the global leader in payment and data security, today announced a strategic partnership with Cassa Centrale Raiffeisen, a leading banking institution, ICIT, an innovative Independent Software Vendor (ISV), and Worldline, [Euronext: WLN], a global leader in payment services. This collaboration brings a new level of payment and data security to All-In-One (AIO) payment devices across Italy's South Tyrol region. South Tyrol is known for its booming economy and status as a premier tourist destination. The thriving tourism, hospitality, and retail sectors make it an ideal environment for advanced and innovative payment technology. The partnership not only facilitates the immediate rollout of AIO devices but also sets the stage for future expansions into unattended and e-commerce payment solutions. By leveraging the expertise of Bluefin, businesses in the region will benefit from robust security and efficient payment processing. 'At Bluefin, we are excited to collaborate with leading players and ISVs to deliver validated P2PE solutions across Europe and all global regions,' said Cheng Chieh Chen, Bluefin's Senior Vice President, Europe. 'Together with Cassa Centrale Raiffeisen, ICIT and Worldline, we are committed to transforming the payment landscape in South Tyrol by delivering payment innovation, security, and enhanced customer experiences to this vibrant market.' 'As the main provider of banking services for Raiffeisen Banks in South Tyrol and as corporate banking experts, we are constantly trying to find new products and solutions to better meet the needs and requirements of our corporate clients and to optimize their work processes. Thanks to our partnership with Bluefin, ICIT and Worldline, we provide innovative and state-of-the-art payment systems to gastronomic businesses in South Tyrol. Thus, we contribute to the economic development of our province,' explained Simon Ladurner, General Director of Cassa Centrale Raiffeisen. 'This ISV partnership, in which Worldline is providing secure and robust payment processing services, will enhance the delivery of an expanded, competitive, and innovative payment offering tailored to the Italian market. Thanks to the partner's combined international experience and local Italian expertise, merchants are assured to receive payment solutions that effectively meet their needs," declared Julia Rachor, Head of SMB Central Sales Management at Worldline. About Bluefin Bluefin is a global leader in payment and data security, specializing in PCI-validated point-to-point encryption (P2PE) and vaultless tokenization to protect cardholder data, PII, and PHI. Our product suite includes both integrated and vendor-agnostic solutions, enabling enterprises, organizations, and SaaS platforms to secure sensitive data with business flexibility. We work with 300+ partners to serve 35,000 clients in 60 countries, securing over 2.5 billion pieces of data annually. Bluefin is headquartered in Atlanta with offices in Waterford, Ireland and Vienna, Austria, and is a Participating Organization of the PCI Security Standards Council (SSC). For more information, visit
